Buscar
Keros Therapeutics Inc
KROSAñadir a la lista de seguimiento
10.070USD
-0.150-1.47%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
199.30MCap. mercado
PérdidaP/E TTM
Más Datos de Keros Therapeutics Inc Compañía
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Información de Keros Therapeutics Inc
Símbolo de cotizaciónKROS
Nombre de la empresaKeros Therapeutics Inc
Fecha de salida a bolsaApr 08, 2020
Director ejecutivoSeehra (Jasbir)
Número de empleados169
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 08
Dirección1050 Waltham Street, Suite 302
CiudadLEXINGTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02421
Teléfono16173146297
Sitio Webhttps://www.kerostx.com/
Símbolo de cotizaciónKROS
Fecha de salida a bolsaApr 08, 2020
Director ejecutivoSeehra (Jasbir)
Ejecutivos de Keros Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
367.50K
+14.97%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
12.34K
+65.97%
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
9.78K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
7.14K
--
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
5.71K
+79.13%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
4.52K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Dr. Alpna Hansraj Seth, Ph.D.
Dr. Alpna Hansraj Seth, Ph.D.
Independent Director
Independent Director
--
--
Dr. Lorena Lerner, Ph.D.
Dr. Lorena Lerner, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
367.50K
+14.97%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Chairman of the Board
Independent Chairman of the Board
12.34K
+65.97%
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
9.78K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
7.14K
--
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
5.71K
+79.13%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Keros Therapeutics Inc?
Los cinco principales accionistas de Keros Therapeutics Inc son: Dr. Jasbir Seehra, Ph.D.
¿Cuántas instituciones poseen acciones de Keros Therapeutics Inc (KROS)?
A fecha de 2026Q1, 427 instituciones poseen acciones de Keros Therapeutics Inc, con un valor de mercado combinado de aproximadamente 22.62M, lo que representa el 114.30% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -32593016.00.